Scaling-Up Production Of Pluripotent Stem Cells Part 1: Begin With The End In Mind

This content was created through a collaboration between Cytiva and CCRM, partners in the Centre for Advanced Therapeutic Cell Technologies (CATCT). CATCT aims to industrialize cell and gene therapy manufacturing processes. CATCT is located in Toronto, Canada.

Many emerging cell and gene therapies are aimed at using cell replacement to regenerate damaged or diseased tissues. Pluripotent stem cells (PSCs) have the potential to generate any cell type in the body and can be considered the raw or input material for cell replacement therapies. In this two-part series of posts, we will look at the steps involved in large-scale manufacturing of PSCs.